These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36702340)

  • 1. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
    Gregg LP; Ramsey DJ; Akeroyd JM; Jafry SA; Matheny ME; Virani SS; Navaneethan SD
    Am J Kidney Dis; 2023 Jul; 82(1):53-62.e1. PubMed ID: 36702340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Eneanya ND; Essien U; Julien H; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Netw Open; 2021 Apr; 4(4):e216139. PubMed ID: 33856475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
    Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
    JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Chu CD; Peralta CA; Du Y; Singh R; Kong SX; Tuot DS; Shlipak MG; Estrella MM
    Diabetes Care; 2022 Dec; 45(12):2900-2906. PubMed ID: 36156061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.
    Ng NM; Ng YS; Chu TK; Lau P
    BMC Prim Care; 2022 Dec; 23(1):317. PubMed ID: 36476327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

  • 11. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
    Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
    Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    Shin JI; Xu Y; Chang AR; Carrero JJ; Flaherty CM; Mukhopadhyay A; Inker LA; Blecker SB; Horwitz LI; Grams ME
    J Am Coll Cardiol; 2024 Aug; 84(8):683-693. PubMed ID: 39142721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
    Nicholas SB; Daratha KB; Alicic RZ; Jones CR; Kornowske LM; Neumiller JJ; Fatoba ST; Kong SX; Singh R; Norris KC; Tuttle KR
    Diabetes Obes Metab; 2023 Oct; 25(10):2970-2979. PubMed ID: 37395334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation.
    Lau D; Pannu N; Yeung RO; Scott-Douglas N; Klarenbach S
    CMAJ Open; 2023; 11(1):E101-E109. PubMed ID: 36720493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.
    Ozaki AF; Ko DT; Chong A; Fang J; Atzema CL; Austin PC; Stukel TA; Tu K; Udell JA; Naimark D; Booth GL; Jackevicius CA
    CMAJ Open; 2023; 11(3):E494-E503. PubMed ID: 37311594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.